AltMountain

Elmind Capital LP

Location not listed · CRD 333910
Hedge fund manager

Elmind Capital LP is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $613.6 million in regulatory assets under management. Its private funds, of all types, hold $613.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +18.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +18.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$613.6 millionForm ADV Item 5.F
Gross assets of private funds
$613.6 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
2Form ADV Item 5.A
Registration
SEC-registered adviserCRD 333910
Latest Form ADV
09/03/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+18.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+18.1%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$398.0 million35 positions, 2026-06-30
$95$107$118Q1 2026Q2 202613F est. $118S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+11.3%+14.8%
Q1 2026+6.1%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 30 share positions ($403,836,290) reported by Elmind Capital, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Celldex Therapeutics Inc New8.91%
  • Legend Biotech Corp7.73%
  • Syndax Pharmaceuticals Inc7.47%
  • Cogent Biosciences Inc6.87%
  • Relay Therapeutics Inc6.55%
  • Amylyx Pharmaceuticals Inc6.45%
  • Viridian Therapeutics Inc6.25%
  • Vaxcyte Inc5.25%
  • Urogen Pharma LTD4.94%
  • Travere Therapeutics Inc4.70%
StockValue% of 13F portfolioSharesShares vs prior quarter
Celldex Therapeutics Inc New$35,975,1008.91%1,110,000+12.12%
Legend Biotech Corp$31,220,8567.73%1,569,676+175.11%
Syndax Pharmaceuticals Inc$30,174,0007.47%1,605,000-13.48%
Cogent Biosciences Inc$27,753,0796.87%866,742-25.97%
Relay Therapeutics Inc$26,448,2866.55%1,465,279Unchanged
Amylyx Pharmaceuticals Inc$26,037,5166.45%894,760+698.89%
Viridian Therapeutics Inc$25,221,3296.25%1,224,931+24.37%
Vaxcyte Inc$21,186,1465.25%372,340-17.69%
Urogen Pharma LTD$19,953,3934.94%491,100+309.25%
Travere Therapeutics Inc$18,994,6884.70%322,600+10.25%
Cullinan Therapeutics Inc$14,778,8573.66%962,792+39.54%
Pharvaris N V$14,456,3903.58%455,750-13.31%
Vera Therapeutics Inc$14,095,1663.49%436,518Unchanged
Cytomx Therapeutics Inc.$12,376,0003.06%4,550,000Unchanged
Beam Therapeutics Inc$11,646,4642.88%476,338Unchanged
Nurix Therapeutics Inc$10,906,6002.70%460,000Unchanged
Summit Therapeutics Inc$8,350,4962.07%493,820Unchanged
United Therapeutics Corp Del$8,128,3502.01%15,000Unchanged
Immunocore Hldgs PLC$7,758,5711.92%256,143+215.67%
Krystal Biotech Inc$7,316,3201.81%22,000Unchanged
Alumis Inc$5,539,2481.37%749,560+15.32%
Biocryst Pharmaceuticals Inc$4,331,6001.07%520,000Unchanged
Sutro Biopharma Inc$3,677,3490.91%228,265+612.50%
MBX Biosciences Inc$3,575,8200.89%61,000-32.97%
DBV Technologies S A$3,116,4000.77%265,000Unchanged
Supernus Pharmaceuticals$3,012,8000.75%70,000Unchanged
Biomarin Pharmaceutical Inc$2,820,0000.70%47,000Unchanged
Septerna Inc$1,934,7440.48%49,444Unchanged
Alector Inc$1,694,4190.42%915,902+1.77%
Design Therapeutics Inc$1,356,3030.34%107,900Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 0 new positions, 5 sold out, 11 increased, 5 reduced and 14 unchanged.

Number of positions (a count, not dollars)

  • New positions0
  • Increased11
  • Unchanged14
  • Reduced5
  • Sold out5

Sold out

StockValue at Jun 30, 2026Shares held then
Insmed Inc$6,930,30065,000
Protagonist Therapeutics Inc$4,658,04038,000
Wave Life Sciences LTD$1,033,285177,846
Tyra Biosciences Inc$638,80020,000
Engene Therapeutics Inc$363,300210,000

Largest increases

StockChange in sharesChangeValue nowShares now
Amylyx Pharmaceuticals Inc+782,760+698.89%$26,037,516894,760
Legend Biotech Corp+999,107+175.11%$31,220,8561,569,676
Urogen Pharma LTD+371,100+309.25%$19,953,393491,100
Immunocore Hldgs PLC+175,000+215.67%$7,758,571256,143
Viridian Therapeutics Inc+240,000+24.37%$25,221,3291,224,931
Cullinan Therapeutics Inc+272,792+39.54%$14,778,857962,792
Celldex Therapeutics Inc New+120,000+12.12%$35,975,1001,110,000
Sutro Biopharma Inc+196,228+612.50%$3,677,349228,265
Travere Therapeutics Inc+30,000+10.25%$18,994,688322,600
Alumis Inc+99,560+15.32%$5,539,248749,560
Alector Inc+15,902+1.77%$1,694,419915,902

Largest reductions

StockChange in sharesChangeValue nowShares now
Cogent Biosciences Inc-303,998-25.97%$27,753,079866,742
Syndax Pharmaceuticals Inc-250,000-13.48%$30,174,0001,605,000
Vaxcyte Inc-80,000-17.69%$21,186,146372,340
Pharvaris N V-70,000-13.31%$14,456,390455,750
MBX Biosciences Inc-30,000-32.97%$3,575,82061,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠